reports
Transgene Sponsored Research Strong TG4050 Data Presented at ASCO
Transgene presented two-year follow-up results from their Ph1 trial of TG4050, an individualised neoantigen therapeutic cancer vaccine, at ASCO. The data demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer.
- Dominic Rose
- Naresh Chouhan
Transgene - Strong TG4050 Data Presented at ASCO (Sponsored Research, ...
Transgene presented two-year follow-up results from their Ph1 trial of TG4050, an individualised neoantigen therapeutic cancer vaccine, at ASCO. The data demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4050 monotherapy generated durable immune responses lasting up to two years and met all trial endpoints, including disease-free survival, immune activation and safety. Remarkably, 100% of patients treated with TG4050 remained disease-free - an exceptio...
Transgene Completes Initial Patient Screening in Phase II Part of TG40...
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by end 2025 First immunogenicity data of Phase II part expected in H2 2026 Preliminary efficacy data expected in H2 2027 Strasbourg, France, June 19, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for th...
Transgene finalise la sélection initiale de patients pour la partie Ph...
Transgene finalise la sélection initiale de patients pour la partie Phase II de l’essai avec TG4050 dans le cancer de la tête et du cou opérable 100 % de survie sans récidive après au moins deux ans de suivi des patients de la partie Phase I de l’essai – preuve de principe clinique démontrée pour TG4050 La randomisation des patients devrait être finalisée d’ici la fin de l’année 2025 Les premières données d’immunogénicité de la partie Phase II sont attendues au deuxième semestre 2026 Les données préliminaires d’efficacité sont attendues au deuxième semestre 2027 Strasbourg, France, 1...
- Emira Sagaama
- Jeremy Garnier
- Martial Descoutures
DGE DIAGEO PLC
RNO RENAULT SA
RI PERNOD RICARD SA
NXI NEXITY SA CLASS A
RCO REMY COINTREAU SA
UNIQA INSURANCE GROUP AG
BLC BASTIDE LE CONFORT MEDICAL SA
KCO KLOECKNER & CO SE
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
EKI EKINOPS SA
VLS VALNEVA SE
LNA LNA SANTE SA
JCQ JACQUET METALS SA
VNA VONOVIA SE
ELG ELMOS SEMICONDUCTOR SE
ALCAR CARMAT SA
TPE PVA TEPLA AG
QDT QUADIENT SA
IMPN IMPLENIA AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
COR CORTICEIRA AMORIM SGPS SA
HEIJM HEIJMANS N.V. CERT
PAL
RIEN PALFINGER AG
AMG RIETER HOLDING AG
EDR AMG ADVANCED METALLURGICAL GROUP N.V.
ZAG EDREAMS ODIGEO SA
POST ZUMTOBEL GROUP AG
INSD OSTERREICHISCHE POST AG
FACC VERIMATRIX SA
AXS FACC AG
HBH ACCSYS TECHNOLOGIES
TRE HORNBACH HOLDING AG & CO. KGAA
SMCP TECNICAS REUNIDAS SA
BFSA SMCP SA
VOS BEFESA SA
BESI VOSSLOH AG
CAF BE SEMICONDUCTOR INDUSTRIES N.V.
MEDCL CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
EAT MEDINCELL SA
GRE AMREST HOLDINGS SE
ALCUR GRENERGY RENOVABLES
FQT ARCURE SA
CLA FREQUENTIS AG WIENER
S30 CLARANOVA SE
ALHGR SOLUTIONS 30 SE
BNTX HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NACON BIONTECH SE
CPR NACON SASU
KTA DAVIDE CAMPARI-MILANO N.V.
UPG KNAUS TABBERT
ALAFY UNIFIEDPOST GROUP
FORSE AFYREN
WAGA FORSEE POWER SA
EAPI WAGA ENERGY SA
ACAG EUROAPI
ARVEN AUSTRIACARD HOLDINGS AG
ORP ARVERNE GROUP SA
LOCAL ORPEA
SOLOCAL GROUP
- Martial Descoutures
- Emira Sagaama
- Martial Descoutures
Transgene to Participate in Upcoming Meetings with Biotech Industry Le...
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025, on June 16, in Boston, US;Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group), on June 18, in Paris, France; Int...
Transgene participera à plusieurs rencontres avec des acteurs clés de ...
Transgene participera à plusieurs rencontres avec des acteurs clés de la biotechnologie Strasbourg (France), le 13 juin 2025, 8 h 30 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, annonce aujourd’hui que son équipe de direction rencontrera des investisseurs institutionnels, des scientifiques et des acteurs du monde de la biotechnologie, lors des prochaines éditions de : BIO International Convention 2025, le 16 juin 2025, à Boston (États-Unis) ;Portzamparc 2025 Mid & Small Caps Con...
- Martial Descoutures
BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im...
BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an Die geplante Übernahme soll die Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer wichtiger Meilenstein in der Umsetzung von BioNTechs Onkologie-StrategieDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen und mRNA-HerstellungÖffentliches Umtauschangebot hinsichtlich aller Aktien von CureVac, bei de...
BioNTech Announces Strategic Transaction to Acquire CureVac in Public ...
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Deposit...
- Jacob Mekhael
Autolus Longer follow up at EHA maintains Aucatzyl's benefit in r/r ad...
Autolus announced updated long term data (approx. 3 years of follow up) from the phase 2 (FELIX) study of Aucatzyl (CD19 CAR-T) in r/r adult ALL to be presented at the European Hematology Association (EHA) conference, being held 12-15 June. The updated results demonstrate that Aucatzyl has maintained its benefit without the need for additional therapy with an additional 11 months of follow up as 38.4% of responders are in ongoing remission (vs. 40% at 21.5 months median follow up). We believe th...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Vranken
- Wim Lewi
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study...
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients still in remission at 24 months38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel LONDON, June 12, 2025 (GLOBE NEWSWIRE...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data...
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025 Strasbourg (France), June 3, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host a live webcast to discuss the latest positive clinical data from its individualized neoantigen cancer vaccine, TG4050, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (see press release ). The webcast will take place on June 6, 2025 at 9:00 a.m. ET / 3:0...
Transgene organise un webinaire sur les résultats positifs de TG4050 d...
Transgene organise un webinaire sur les résultats positifs de TG4050 dans les cancers de la tête et du cou présentés à l’ASCO 2025 Strasbourg, France, le 3 juin, 8h00 CET – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce la tenue d’un webinaire en direct pour commenter les dernières données cliniques positives de TG4050, son vaccin thérapeutique individualisé contre le cancer qui ont été présentées lors du congrès annuel 2025 de l’American Society of Clinical Oncology (ASCO)...
Immunocore to present at the 2025 Jefferies Global Healthcare Conferen...
Immunocore to present at the 2025 Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference. 2024 Jefferies Global Healthcare ConferenceFireside Chat: Thursday, June 5, 2025, at 11:05 a.m. EDT The presentation will be ...
BioNTech und Bristol Myers Squibb geben globale strategische Partnersc...
BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard zu setzen, der über die traditionellen Checkpoint-Inhibitoren hinausgehtDie Kollaboration zur gemeinsamen Entwicklung und Kommerzialisierung mit einer 50:50-Gewinn-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.